Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt Sells 700 Shares

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) VP Padmanabh P. Bhatt sold 700 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total transaction of $27,734.00. Following the transaction, the vice president now directly owns 10,149 shares in the company, valued at $402,103.38. The trade was a 6.45 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Supernus Pharmaceuticals Trading Down 0.8 %

Shares of SUPN stock traded down $0.32 during trading hours on Friday, hitting $38.37. 325,652 shares of the company were exchanged, compared to its average volume of 298,294. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $39.88. The business has a 50 day moving average of $37.14 and a two-hundred day moving average of $34.53. The company has a market capitalization of $2.12 billion, a PE ratio of 35.86 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last released its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.25. The firm had revenue of $175.70 million during the quarter, compared to analysts' expectations of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The company's revenue was up 14.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.29) EPS. On average, research analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on SUPN. Cantor Fitzgerald assumed coverage on shares of Supernus Pharmaceuticals in a research report on Monday, January 6th. They set an "overweight" rating and a $57.00 price target on the stock. Piper Sandler reissued a "neutral" rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Finally, Cowen reaffirmed a "buy" rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several hedge funds have recently made changes to their positions in SUPN. Barclays PLC grew its position in Supernus Pharmaceuticals by 88.3% in the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company's stock valued at $3,393,000 after purchasing an additional 51,005 shares in the last quarter. Segall Bryant & Hamill LLC acquired a new stake in shares of Supernus Pharmaceuticals in the third quarter valued at about $791,000. Geode Capital Management LLC boosted its position in Supernus Pharmaceuticals by 5.3% during the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company's stock valued at $46,218,000 after purchasing an additional 74,438 shares during the last quarter. Franklin Resources Inc. grew its stake in Supernus Pharmaceuticals by 7.6% in the third quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company's stock valued at $987,000 after purchasing an additional 2,121 shares in the last quarter. Finally, Bank of Montreal Can raised its stake in shares of Supernus Pharmaceuticals by 1,508.0% during the 2nd quarter. Bank of Montreal Can now owns 116,322 shares of the specialty pharmaceutical company's stock worth $3,287,000 after purchasing an additional 109,088 shares in the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.